TriangleNCT02213926 · CITED IN SOURCE DOCUMENTS
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE2
- Status at capture
- ACTIVE NOT RECRUITING
- Registry last update
- 2026-08-04
The purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL).
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- Inclusion criteria: * Men and women ≥ 18 years of age. * Pathologically confirmed MCL, with documentation of monoclonal B cells that have a chromosome translocation t(11;14)(q13;q32) and/or overexpress cyclin D1. * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2. * Agreement to use contraception during the study and for 30 days after the last dose of study drugs if sexually active and able to bear or beget children. Exclusion criteria: * A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ACP-196 (acalabrutinib), or put the study outcomes at undue risk * Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or corrected QT interval (QTc) \> 480 msec. * Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction. * Breast feeding or pregnant
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- ACP-196 (acalabrutinib) Regimen 1
- intervention Names
- Drug: ACP-196 (acalabrutinib)
- label
- ACP-196 (acalabrutinib) Regimen 1
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- ACP-196 (acalabrutinib) Regimen 1
- name
- ACP-196 (acalabrutinib)
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 124
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- The overall response rate (ORR) is defined as the proportion of subjects achieving either a partial remission (response) (PR) or complete response (CR) according to the Lugano Classification for NHL (Cheson 2014) as assessed by investigators, where SD stands for Stable Disease, PD for Progressive Disease and NE for Not Evaluable.
- measure
- Overall Response Rate (ORR) of ACP-196 (Acalabrutinib) in Subjects With Previously Treated MCL.
- time Frame
- From the date of the first dose until 30 days after the last dose of the study drug or start of a new anti-cancer treatment, whichever came first, assessed up to approximately 4 year and 10 months. 1 cycle =28 days
Full study description
- brief Summary
- The purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL).
- detailed Description
- This clinical trial is a Phase 2, multicenter, (approximately 70 global centers), open-label study in subjects with histologically documented MCL, who have relapsed after, or were refractory to, ≥ 1 (but not \> 5) prior treatment regimens. Subjects will be enrolled and will take 100 mg of acalabrutinib twice per day (BID) in repeated 28-day cycles. Treatment with acalabrutinib may be continued until disease progression or an unacceptable drug-related toxicity occurs. Dose modification provisions are provided in the study protocol. All subjects will have hematology, chemistry, and urinalysis safety panels done at screening. Once dosing commences (Day 1), all subjects will be evaluated for safety, including serum chemistry and hematology, once weekly for the first 4 weeks, every 2 weeks in Cycle 2, every 4 weeks in Cycles 3 to 12, and every 24 weeks thereafter. PK/PD testing will be done in Cycles 1 and 2. Tumor assessments will be completed at 8- to 24-week intervals during the trial.
Source references
- references
- citation
- Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018 Feb 17;391(10121):659-667. doi: 10.1016/S0140-6736(17)33108-2. Epub 2017 Dec 11.
- pmid
- 29241979
- type
- DERIVED
- see Also Links
- label
- redacted CSP
- label
- redacted CSR Synopsis
- label
- redacted SAP
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-1314a5c2ef4f511a248a
- requested nct id
- NCT02213926
- primary nct id
- NCT02213926
- source kind
- fda_spl_label
- source record id
- 7365aa18-60da-4ce6-9c06-01c80e158286
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- payload sha256
- c434b9bd004a1e80003b27913e4d3c8a02883a381697b1a60d87f36c83d52682
- payload
- application numbers
- NDA216387
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-1314a5c2ef4f511a248a
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02213926
- occurrences
- context exact
- mphoma ACE-LY-004 The efficacy of CALQUENCE was based upon Trial LY-004 titled “An Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma” (NCT02213926). Trial LY-004 enrolled a total of 124 patients with MCL who had received at least one prior therapy. The median age was 68 (range 42 to 90) years, 80% were ma
- end
- 4055
- exact text
- NCT02213926
- start
- 4044
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00400.json
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source json pointer
- /results/52/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 7365aa18-60da-4ce6-9c06-01c80e158286
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- f9bc3eb9cfa20e7226fa919f15ceefcf049fb7acde4f5ee38ef2fa4b1fda28e9
- spl effective time
- 20260219
- spl set id
- b1409184-3267-4d8c-8f17-4e01f69828b1
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-9d71ac6da6295f06bf34
- requested nct id
- NCT02213926
- primary nct id
- NCT02213926
- source kind
- fda_spl_label
- source record id
- aa4e8627-21c7-413a-9d0d-1957ded93283
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- payload sha256
- a31cff692cf175e10c7efc47a3ff241cc0c094b980c4d8688364a1a1e04aa735
- payload
- application numbers
- NDA210259
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-9d71ac6da6295f06bf34
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02213926
- occurrences
- context exact
- mphoma ACE-LY-004 The efficacy of CALQUENCE was based upon Trial LY-004 titled “An Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma” (NCT02213926). Trial LY-004 enrolled a total of 124 patients with MCL who had received at least one prior therapy. The median age was 68 (range 42 to 90) years, 80% were ma
- end
- 3969
- exact text
- NCT02213926
- start
- 3958
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00500.json
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source json pointer
- /results/91/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- aa4e8627-21c7-413a-9d0d-1957ded93283
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 7499e5b4aaef0e67b2fa5389a487f9dd4346bdfbc2c55f29a32af05aa0e256f3
- spl effective time
- 20260219
- spl set id
- dd4835ef-e1bc-4997-a399-1ffa2556fbfe
Preserved source evidence · Not medical advice